News

David Sackler, Nutroganics’ President & CEO, said, "We are pleased to announce this first step in increasing the disclosure and transparency of the operations and performance of Nutroganics

The patent, which has also been granted to Pluristem in Australia, Russia and South Africa, covers the Company’s key technology platform, its method for 3-dimensional expansion of placental

Pristima is software as a service (SaaS) model that consolidates several systems and applications into a single, global solution. As part of the deal, Pfizer will implement a

Data from two clinical trials was presented at the American Diabetes Association 74th Scientific Sessions. In the two-year trial, empagliflozin in combination with certain other diabetes therapies showed

The company said that Lymphoseek becomes the first and only FDA-approved radiopharmaceutical application for sentinel lymph node detection and was first approved in March 2013 for lymphatic mapping

As part of the deal, the option to license extended to Celgene through the end of Phase I, but AG-221 has been exercised early based on the Phase

The FDA approval is based on priority review of two, multi-center, Phase III studies GEMMA-1 and GEMMA-2 carried out in 13 countries. The GEMMA principal investigator Gillian Newsteads

As part of the deal, Veristat will provide strategic statistical consulting and biometrics services, including study design, statistical analysis and data presentation, for a number of new cancer

OncoMed has been informed by the participating clinical sites of recent on-target mild-to-moderate bone-related adverse events for the two programs. To date, bone-related adverse events have been observed